High-dose olanzapine versus standard-dose olanzapine: Effect on all-cause readmission rates in adult psychiatric patients
Mental Health Clinician · 2026-08 · 16 (4) · 196-201
DOI: 10.9740/mhc.2026.08.196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mental Health Clinician, 2026-08. Verfasst von Teressa Benbarka und 1 weiteren Autor:innen. Beteiligte Einrichtung: PGY-2 Psychiatric Pharmacy Resident, Riverside University Health System Medical Center, Riverside, CA. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Psychiatrische Pflege
Abstract (Originalsprache)
Introduction
Olanzapine doses in adults with treatment-resistant schizophrenia or treatment-resistant schizoaffective disorder have been compared in a few open-label trials, with higher doses associated with increased symptom improvement. The most significant adverse effects observed at off-label doses above 30 mg/day have been weight gain, sedation, or drowsiness.
Methods
This single-center, retrospective cohort study aimed to evaluate patient factors and outcomes in adult patients admitted to a county psychiatric hospital that received high-dose olanzapine therapy (HD-olanzapine, ≥40 mg/day) compared with standard-dose olanzapine (SD-olanzapine, 5-30 mg/day). Patients 18 years or older were included if they received at least 5 days of scheduled olanzapine treatment for psychotic symptoms or psychosis while admitted.
Results
Subjects on HD-olanzapine (n = 139) and SD-olanzapine regimens (n = 70) were on average 35 years of age, and most were White. There was no statistical difference regarding 30-day all-cause readmissions, 30-day all-cause emergency-treatment service visits, or average duration of olanzapine therapy. The average length of stay was longer in the HD-olanzapine group (31.3 days vs 14.5, P = 0.009). Constipation was more common in the HD-olanzapine group (8.6% vs 1.4%, P = 0.0418).
Discussion
Although 30-day all-cause readmissions and emergency-treatment service visits were similar between groups, patients who received olanzapine doses of 40 mg/day or greater for at least 5 days of treatment experienced significantly longer average length of stay and more constipation during an admission.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- PGY-2 Psychiatric Pharmacy Resident, Riverside University Health System Medical Center, Riverside, CA.
- (Corresponding author) Supervising Clinical Pharmacist, Riverside University Health System Medical Center, Riverside, CA, Andrew.williams@ruhealth.org.
ORCID-Profile: Teressa Benbarka, Andrew Williams
Zitieren
APA
Benbarka, T., & Williams, A. (2026). High-dose olanzapine versus standard-dose olanzapine: Effect on all-cause readmission rates in adult psychiatric patients. Mental Health Clinician, 16(4), 196-201. https://doi.org/10.9740/mhc.2026.08.196
Vancouver
Benbarka T, Williams A. High-dose olanzapine versus standard-dose olanzapine: Effect on all-cause readmission rates in adult psychiatric patients. Mental Health Clinician. 2026;16(4):196-201. doi:10.9740/mhc.2026.08.196
BibTeX
@article{Benbarka2026,
author = {Benbarka, Teressa and Williams, Andrew},
title = {High-dose olanzapine versus standard-dose olanzapine: Effect on all-cause readmission rates in adult psychiatric patients},
journal = {Mental Health Clinician},
year = {2026},
volume = {16},
number = {4},
pages = {196--201},
doi = {10.9740/mhc.2026.08.196}
}
EUVIMED